Status:
UNKNOWN
Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study
Lead Sponsor:
McGill University
Conditions:
Cutaneous T-Cell Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This is an open label, prospective study to evaluate therapeutic potential of Tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study...
Eligibility Criteria
Inclusion
- Patients with Stage I-IIA CTCL must be at least 18 years of age with a skin biopsy prior to enrolment confirming the diagnosis of mycosis fungoides.
Exclusion
- Patients with Stage \>IIA CTCL at the time of enrolment
- Women who are pregnant or planning to get pregnant, or unable/unwilling to use adequate contraception
- Patients who were treated with topical retinoid therapy in the past 3 months
- Patients who received any systemic CTCL therapy or systemic corticosteroid therapy within 30 days of the study start date
- Patients who were treated with systemic isotretinoin or bexarotene within 3 months prior to the study start date, systemic acitretin within 2 years prior to study start date
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2012
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00779896
Start Date
October 1 2008
End Date
December 1 2012
Last Update
October 24 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
McGill University
Montreal, Quebec, Canada, H2W 1S6